Earnings Feed
Start Free
Home/Filings/3/0000899243-19-018436
3//SEC Filing

ARCH Venture Partners IX, LLC 3

Accession 0000899243-19-018436

CIK 0001771917other
View on SEC.govCompany Profile

Filed

Jun 26, 8:00 PM ET

Accepted

Jun 27, 5:18 PM ET

Size

22.7 KB

Accession

0000899243-19-018436

Insider Transaction Report

Form 3
Period: 2019-06-27
Karuna Therapeutics, Inc.KRTX
ARCH Venture Partners IX, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,644 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,793 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,643 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,792 underlying)
ARCH Venture Partners IX Overage, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,643 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,792 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,644 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,793 underlying)
ARCH Venture Fund IX, L.P.
10% Owner
Holdings

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,793 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,643 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,792 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,644 underlying)
ARCH Venture Partners IX, LLC
10% Owner
Holdings

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,793 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,643 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,644 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,792 underlying)
BYBEE CLINTON
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,643 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,792 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,793 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,644 underlying)
ARCH Venture Fund IX Overage, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,644 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,643 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,793 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,792 underlying)
CRANDELL KEITH
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,643 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,793 underlying)

  • Series B Preferred Stock

    (indirect: See Footnote)
    → Common Stock (857,792 underlying)

  • Series A Preferred Stock

    (indirect: See Footnote)
    → Common Stock (723,644 underlying)
Footnotes (4)
  • [F1]The Series A Preferred Stock is convertible on a 1.2987-for-one basis into the number of shares of Common Stock shown in Column 3. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock has no expiration date.
  • [F2]These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
  • [F3]These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
  • [F4]The Series B Preferred Stock is convertible on a 1.2987-for-one basis into the number of shares of Common Stock shown in Column 3. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Preferred Stock has no expiration date.

Documents

2 files

Issuer

Karuna Therapeutics, Inc.

CIK 0001771917

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001723174

Filing Metadata

Form type
3
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 5:18 PM ET
Size
22.7 KB
View on SEC.gov